RESUMO
PURPOSE: To compare the effectiveness of three consecutive intravitreal injections of bevacizumab (Avastin) and ranibizumab (Lucentis) in patients with treatment-naïve neovascular age-related macular degeneration. METHODS: This is a retrospective comparative study of qualifying consecutively treated patients (n = 176) with new-onset subfoveal choroidal neovascularization presenting at 6 retina referral centers. Patients were treated with 3 consecutive monthly injections of ranibizumab (0.5 mg) or 3 injections of bevacizumab every 6 weeks (1.25 mg) as determined by physician and patient preference. Ophthalmologic evaluations included monthly visual acuity measurements, ocular examinations, and optical coherence tomography imaging at each visit. RESULTS: A 29.2% reduction in the mean central foveal thickness measurement through optical coherence tomography was found in the ranibizumab-treated patients versus a 20.9% reduction in the bevacizumab-treated patients (P Assuntos
Inibidores da Angiogênese/administração & dosagem
, Anticorpos Monoclonais/administração & dosagem
, Neovascularização de Coroide/tratamento farmacológico
, Degeneração Macular/tratamento farmacológico
, Idoso
, Anticorpos Monoclonais Humanizados
, Bevacizumab
, Neovascularização de Coroide/etiologia
, Neovascularização de Coroide/fisiopatologia
, Feminino
, Angiofluoresceinografia
, Humanos
, Injeções
, Degeneração Macular/complicações
, Degeneração Macular/fisiopatologia
, Masculino
, Ranibizumab
, Retina/patologia
, Estudos Retrospectivos
, Tomografia de Coerência Óptica
, Resultado do Tratamento
, Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
, Acuidade Visual/fisiologia
, Corpo Vítreo